Tafamidis

Phase 3

PFIZER (PFE)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Transthyretin (TTR) Amyloid Cardiomyopathy

View Full Landscape

Drug Information

Target Indication

Transthyretin (TTR) Amyloid Cardiomyopathy

Clinical Trial

NCT02791230

Last updated: 12/19/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA9/18/2026

Tafamidis Accord

Tafamidis Accord is indicated for the treatment of hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTRh-CM).

View on EMA

EMA11/16/2011

Vyndaqel

Vyndaqel is indicated for the treatment of transthyretin amyloidosis in adult patients with stage-1 symptomatic polyneuropathy to delay peripheral neurologic impairment.

Orphan

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

PFE

PFIZER

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

13 valent pneumococcal conjugate vaccine with Polysorbate 80Phase 3

Vaccines, Pneumococcal

Insulin LisproPhase 3

Diabetes Mellitus

Cyclosporine APhase 3

Renal Transplantation

DVS-233 SR (desvenlafaxine sustained release )Phase 3

Major Depressive Disorder

MeropenemPhase 3

Complicated Intra-abdominal Infections

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts